Success Metrics

Active Trials
3(100%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_4
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 21 (50.0%)
Phase 41 (50.0%)

Trials by Status

active_not_recruiting133%
recruiting267%

Recent Activity

3 active trials
Showing 3 of 3
recruitingphase_2

Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology

NCT06856525
active_not_recruitingphase_4

Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis

NCT04467957
recruiting

Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma

NCT07139899

Clinical Trials (3)

Showing 3 of 3 trials
NCT06856525Phase 2

Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology

Recruiting
NCT04467957Phase 4

Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis

Active Not Recruiting
NCT07139899

Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3